Daniel J. Booser

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

Aman U. Buzdar, Nuhad K. Ibrahim, Deborah Francis et al. · Journal of Clinical Oncology · 2005 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +17

Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer

Kenneth R. Hess, K. Anderson, W. Fraser Symmans et al. · Journal of Clinical Oncology · 2006 · 728 citations

Medicine, Oncology, Pharmacology +13

Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer

Francisco J. Esteva, Vicente Valero, Daniel J. Booser et al. · Journal of Clinical Oncology · 2002 · 572 citations

Medicine, Oncology, Pharmacotherapy +17

Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer

Mark Ayers, W. Fraser Symmans, James Stec et al. · Journal of Clinical Oncology · 2004 · 569 citations

Medicine, Cancer Biology, Oncology +17

Management of Breast Cancer During Pregnancy Using a Standardized Protocol

David L. Berry, Richard L. Theriault, Frankie A. Holmes et al. · Journal of Clinical Oncology · 1999 · 426 citations

Medicine, Obstetrics, Oncology +16